Dicerna

Dicerna Pharmaceuticals, Inc. was founded in 2007 as a biopharmaceutical company dedicated to developing innovative therapies for rare genetic diseases. Dicerna utilizes its proprietary GalXC™ and GalXC-Plus™ RNAi technologies to develop RNAi-based therapies for the treatment of rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular conditions. In addition to our own core discovery and clinical candidate pipeline, Dicerna has established partnerships with some of the world’s leading pharmaceutical companies.